t.
Torre
s VE. Polycystic Kidney Disease Aulosomal-Dominanı and Recessive Forms. In: Massry SG, Glassock RJ (eds) Massry and Glassock's Textbook of Nephrology. Uppincott Williams and Wilkins, Philadelphia 2001, pp 896-904.
2. O'Stillivan DA, Torres VE. Autosomal Dominant Polycystic Kidney Disease. In: Johnson RJ, Fechally J (eds) Comprehensive Clinical Nephrology. MOSBY, London 2000, pp 9.49.1¬9.49.12.
10
Türk
Nefroloj
i Diyaliz ve Transplantasyon Dergisi /Official Journal of the Turkish Society of Nephrology
Polikistik Böbrek Hastalığında Kistogenczde Yenilikler #
ı.
Gaho
w PA. Autosomal dominanc polycystic kidney disease.
N Engl J Med 1993329:332-342. i. Wilson PD. Polycystic kidney disease. N Engl J Med 2004;
350:1^1-164.
i. Parlrey PS. BearJC. Morgan I el al. The diagnosis and prognosis of autosomal dominant polycystic kidney disease.N Engl J Med 1990;323:1085-1090.
». Igarashi P. Somlo S, Genetics ami pal Oogenesis of polycystic kidney disease..! Am Soc Nephrol 2002;13:2384-2398.
'. Torres VE, Harris PC. Mechanism of disease: autosomal dominant and recessive polycystic kidney diseases. Nature Clinical Practice Nephrology 2006;2: 10-55.
I. Mpfhizuki T. Wu G, Hayashi T et al. PKD2, a gene for polycystic kidney disease that encodes an integral membrane protein. Science I996;272:1339-I3i2.
I. Grantham J|. GetserJL, Evan AP. Cyst formation and growth in autosomal dominant polycystic kidney disease. Kidney Ini 198731:1145-1152.
o. Qian F, Watnick TJ, Onuchic LF, Genuine GG. The molecular hasis of focal cyst formation in human autosomal dominant polycsytic kidney disease type I. Cell 1990;87:979-987.
II. Nadasdy T, Laszik /.. Lajoie G. Blick KE, Wheeler DE; Silva Eti. Proliferative activity of cyst epithelium in human renal cystic diseases. | Am Soc Nephrol IW:i;5:l-i62-1468.
12. I)ıı J, Wilson PD. Abnormal polarization of EGF receptors and autocrine stimulation of cyst epithelial growth in human ADPKT). Am j Physiol 1995;2Ğ9:€487-C495<
13. Sweeney WT.. Chen Y, Nakanishi K. Frost P. Avner ED. Treatment i>l polycystic kidney disea.se with a novel tyrosine kinase inhibitor. Kidney Int 2000;57:33-40,
ft. Stocklin E. Boiteri F. Groner B. An activated allele of the c-
erbB*2 oncogene impairs kidney and lung function and causes early death of transgenic mice. J Cell Biol 122: 199-208. 1993
15. Richards WG, Sweeney WE. Yoder BK, Wilkinson JE, Woyc-hik RP, Avner ED. Epidermal growth factor receptor activity mediates renal cyst formation in polycystic kidney disease. J Clin Invest 1998;101:935-939.
16. Woo D, Apoptosis and loss of renal tissue In polycystic kidney diseases. N Engl [ Med 1995:333:18-2'».
17. Veis DJ, Sorenson CM, Shutter JR, Korsmeyer SJ. Bcl-2 deficient mice demonstrate fulminant lymphoid apoptosis, polycystic kidneys and hypopigmented hair. Cell I993;75: 229-240.
18. Lin HH, Yang TP, Jiang ST, Yang HY, Tang MJ. Bcl-2 ove-rexpression prevents apoptosis-induce d Madin-Darby canine kidney simple epithelial cyst formation Kidney !nl 1999:55: 168-178.
19. Ecder T, Melnikov VY. Stanley M et al. Caspases, Bcl-2 proteins and apoptosis in autosomal-dominant polycystic kidney disease. Kidney Int 2002;61:1220-1230.
20. Grantham JJ, Ye M, Davidow C et al. Evidence for a potent lipid secretagogue in the cyst fluids of patients with autosomal dominant polycsytic kidney disease. | Am Soc Nephrol 1995;6:1242-1249.
21. Grantham JJ. The etiology, pathogenesis, and treatment of autosomal dominant polycystic kidney disease: recent advances. Am J Kidnet Dis 1996;28:788-803.
22. Torres VE, Wang X. Qian Q, Somlo S, Harris PC, GattOne VII 2nd. Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease. Nat Med 20TH;10: 363-364.
Thank you for copying data from http://www.arastirmax.com